Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 3/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128724 | 0.98 | CYP3A4 (0.61) | CYP3A4GPR119CYP2C9KCNH2PIK3CA | |
| SCHEMBL1128465 | 0.89 | CYP3A4 (0.59) | CYP3A4GPR119CYP2C9KCNH2PIK3CA | |
| SCHEMBL1128407 | 0.89 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9KCNH2 | |
| SCHEMBL2016500 | 0.87 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9PIK3CAMTOR | |
| SCHEMBL2016396 | 0.87 | CYP3A4 (0.57) | CYP3A4GPR119CYP2C9KCNH2PIK3CA | |
| SCHEMBL1128367 | 0.86 | CYP3A4 (0.57) | CYP3A4GPR119CYP2C9KCNH2PIK3CA | |
| SCHEMBL1128417 | 0.85 | CYP3A4 (0.60) | CYP3A4CYP2C9RETEGFRBTK | |
| SCHEMBL1128336 | 0.85 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9PIK3CAMTOR | |
| SCHEMBL2017035 | 0.85 | CYP3A4 (0.55) | CYP3A4GPR119CYP2C9KCNH2PIK3CA | |
| SCHEMBL2015012 | 0.85 | CYP3A4 (0.50) | CYP3A4GPR119CYP2C9KCNH2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | claimed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | METABOLEX, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160222-A1 | MODULATORS OF GLUCOSE HOMEOSTASIS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, GCKR, GID4 | CYP3A4 789/4885GPR119 1/4885CYP2C9 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.